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We present a case of a 79-year-old male who presented with retroperitoneal hematoma a week after motor vehicle accident. Prior
history and family history of bleeding were nonsigni2cant. His activated partial thromboplastin time was found to be prolonged in
the emergency department. Further workup with coagulation studies showed decreased factor VIII, vWF antigen, and vWF:
ristocetin cofactor assay, and negative Bethesda assay, indicating acquired vonWillebrand disease. Immuno8uorescence to 2nd an
underlying etiology was suggestive of MGUS. Management of AvWD depends on controlling active bleeding and treating the
underlying cause. He was treated with factor VIII, haemate-p, rituximab, two cycles of IVIg, and three weeks of oral steroids.
1. Introduction
Acquired von Willebrand disease (AvWD) is a rare bleeding
disorder [1, 2]. It is characterized by hemorrhagic events
later in life without personal or family history of bleeding
events [3]. A number of acquired conditions have been
associated with AvWD [4]. We report a patient diagnosed
with acquired von Willebrand disease secondary to mono-
clonal gammopathy with unknown signi2cance after initial
presentation with retroperitoneal hematoma.
2. Case Description
A 79-year-old man presented to the emergency department
with severe left hip and groin pain with overlying hematoma.
He had a prior admission one week before with arrhythmia-
induced syncope leading to a motor vehicle accident. He
received a dual-chamber automatic implantable cardioverter-
de2brillator after inducible ventricular 2brillation/ventricular
tachycardia during electrophysiology study. CT scan at the
time was unremarkable except for a 2 cm area of suspected
hematoma in the left trochanteric region. His past medical
history and medications were not signi2cant except for
aspirin use. (e patient denied signi2cant prior or family
history of bleeding or easy bruising. He had undergone an
appendectomy and bilateral hip replacements in the past
without signi2cant bleeding.
(e patient was hypotensive on presentation. His he-
moglobin had dropped from 11.7 g/dl to 6.2 g/dl within one
week. CT scan of his chest/abdomen/pelvis revealed a large
left retroperitoneal hematoma measuring approximately
14.2× 6.8×14.1 cm (Figure 1). (e patient’s PTT was 48 s,
which increased from 38 s a week ago (Table 1). His pro-
thrombin time was 13.9 s with INR of 1.1. His white blood
count and platelet count were normal. Serum 2brinogen,
2brin degradation products and d-dimer, and liver function
tests were normal. His factor VIII activity was 12%, and von
Willebrand factor antigen was 4%. vWF had normal mul-
timeric distribution. His vWF:ristocetin cofactor assay
was< 20. (e Bethesda assay (factor VIII inhibitor screen-
ing) was negative for an inhibitor. Circulating anticoagulant
screening (mixing study) failed to correct his PTT which
suggested the possibility of an inhibitor or lupus antico-
agulant. Although he was positive for lupus anticoagulant
(anti-LA 67), dilute Russell viper venom time (DRVVT)
ratio was 1. (us, we ruled out antiphospholipid antibody
Hindawi
Case Reports in Oncological Medicine
Volume 2017, Article ID 9295780, 3 pages
https://doi.org/10.1155/2017/9295780
syndrome and diagnosed the patient’s condition as ac-
quired von Willebrand factor de2ciency. (e patient was
resuscitated with 3 units of packed red blood cells and
prothrombin complex concentrate. He underwent factor
VIII 50% replacement, one dose of haemate-p (3976 units),
one cycle of rituximab, and three weeks of oral steroids. He
also received two cycles of IVIg which normalized vWF
antigen or factor VIII activity. His aPTT was 34.9 s, factor
VIII activity was 114%, von Willebrand factor antigen was
95%, and vWF:ristocetin cofactor assay was 81%.
Evaluation of underlying etiology showed decreased
albumin and IgG with normal IgA and IgM on serum
electrophoresis. Immuno8uorescence showed a band in IgG
lambda suggestive of an early monoclonal protein (0.34 g/dL
of the total 0.68 g/dL of protein in the gamma region).
Kappa/lambda ratio was 0.70 (normal reference range
0.26–1.65). He was diagnosed with monoclonal gammop-
athy of unknown signi2cance. Bone marrow biopsy to rule
out myeloma was not done. CT scans of head, chest, ab-
domen, and pelvis done were negative for lytic bone lesions
or lymphadenopathy. He had normal renal function and
normal serum calcium. Iron pro2le showed ferritin of
925 ng/ml (27–300 ng/dl), iron of 25mcg/dl (40–175mcg/dl),
and transferrin of 125mg/dl (193–378mg/dl). Ferritin was
most likely elevated from blood transfusions. Folate and
vitamin B12 were normal. ANA, hepatitis B, and hepatitis
C were negative. (yroid function test was normal. Echo-
cardiogram showed mild aortic stenosis. He was discharged
on 40mg prednisone daily after bleeding was controlled.
His hemoglobin level on discharge was 9.8 gm/dl.
On follow-up after a month on prednisone, his aPTT was
34.9, factor VIII activity was 114%, von Willebrand factor an-
tigen was 95%, and vWF:ristocetin cofactor assay was 81%. His
hemoglobin was 11.8 g/dl. Repeat iron studies were not done.
3. Discussion
Acquired vWS is a rare condition [5]. It is associated with
a multitude of conditions, including lymphoproliferative
disorders (most common: 48%), myeloproliferative disorders
(chronic granulocytic leukemia, essential thrombocythemia,
and polycythemia vera), neoplasms (Wilms tumor), immu-
nological disorders, cardiovascular diseases, hypothyroidism,
hemoglobinopathies, drugs (valproate, cipro8oxacin, and
hydroxyethyl starch), and infections [1, 2, 4–7]. Among
lymphoproliferative disorders, MGUS is the most com-
monly associated with AvWD, including in 23% of regis-
tered patients [1]. Other lymphoproliferative disorders
Figure 1: CT scan of the abdomen with retroperitoneal hematoma.
Table 1: Lab tests done during presentation, treatment, and a month after treatment.
Lab test Presentation During treatment (3 days) 1 month after treatment Reference range
INR 1.1 N/A 1.1 0.9–1.1
PTT (sec) 48 N/A 34.9 23–34 s
Factor VIII activity (%) 12 33 114 50–160%
Factor IX activity (%) 166 N/A N/A 60–150%
Factor XI activity 98 N/A N/A 50–150%
Factor XII activity 54 N/A N/A 50–150%
vWF antigen (%) 6 10 95 60–150%
Ristocetin cofactor assay (%) < 20 < 20 81 50–160%
vWF multimer analysis Normal N/A N/A Normal multimeric distribution
Bethesda assay 0 N/A N/A 0
INR: international normalized ratio; PTT: partial thromboplastin time; vWF: von Willebrand factor; N/A: not available.
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associated with acquired vWD are MM, Waldenstrom
macroglobulinemia, CLL, HCL, NHL, and lymphosarcoma
[3]. (ere are two proposed mechanisms for acquired vWD.
Immune mechanism is believed to be the responsible
mechanism in patients with lymphoproliferative or auto-
immune diseases. Nonspeci2c antibodies bind to vWF; this
complex gets cleared by FC-bearing cells or autoantibodies
directed against the vWF [5, 8]. In MGUS, as in our patient,
paraproteins bind to vWF resulting in accelerated clearance
and low circulating levels [2]. Immune-mediated cause most
likely mediates the disease process in our patient, as he had
signi2cant response to IVIg. Nonimmune-mediated mecha-
nisms are thought to be due to loss of large vWF multimers
under high shear stress conditions (congenital heart defects,
aortic stenosis, arti2cial heart valves, or left ventricular assist
device), absorption of vWF onto tumor cells, decreased
synthesis (hypothyroidism and valproic acid) or release
from endothelial cells, or increased proteolysis of vWF
(cipro8oxacin) [2, 4, 5].
Presentation in acquired vWD is similar to congenital
vWD. However, AvWD presents later in life with no pre-
vious or family history of bleeding [9, 10]. Routine rec-
ommended tests in acquired von Willebrand disease are
vWF:Ag assay, vWF:Ag activity assay, and ristocetin cofactor
assay (vWF:RCo/Ag ratio) (normal 1) [2, 7]. Among them,
ristocetin cofactor assay is the recommended test [7]. vWF:
RCo/Ag ratio< 0.6–0.7 indicates inhibitory antibodies or
a selective loss or decrease in high molecular weight mul-
timers [2]. Circulating inhibitors are rarely detected in this
condition [4]. vWF multimer analysis is the gold standard
test. It is particularly useful if other tests are negative [2].
A multimeric pattern with decreased levels of high molec-
ular weight vWF multimers is seen because the inhibitors
tend to attack the large multimers of vWF. Serum protein
electrophoresis or immuno8uorescence tests and thyroid
function test can be done to establish etiology [4]. Con-
genital vWD and AvWD can be diNerentiated by mea-
surement of vWF propeptide (vWFAg II). vWF propeptide
is a marker of vWF synthesis. Since AvWD is associated
with clearance of vWF, vWF propeptide will be normal [4].
4. Management
Management is based on correction of acute bleeding epi-
sode and treatment of associated underlying conditions.
(e acute bleeding can be controlled by infusion of cry-
oprecipitate, vWF-containing factor VIII (FVIII) concen-
trates (haemate-p), or desmopressin. (is will result in
immediate and transient rise in serum FVIII-vWF complex
levels [4]. IVIg can correct vWF activity for 2–3 weeks [2].
IVIg is the preferred to minimize bleeding risk during elective
procedures [1]. A combination of IVIg, vWF-containing
factor VIII (FVIII) concentrates (haemate-p), and desmo-
pressin is eNective in some patients [5]. FVIII and vWF levels
return to baseline within 2 hours of transfusion of haemate-p
[11]. In patients with MGUS, steroids and rituximab have
been used to treat AvWD [5]. Rituximab, which is eNective in
acquired hemophilia, has been used in treatment for a few
cases. However, it has been reported to be ineNective in them
[12]. Management of aortic stenosis, hypothyroidism, and
discontinuation of medications has resulted in correction of
the bleeding disorder [2].
5. Conclusion
AvWD should be considered in cases with abnormal
bleeding and prolonged PTT. It can be asymptomatic inmild
conditions for decades [2]. Further workup for an etiology is
important as treatment of the underlying cause can prevent
future bleeding episodes.
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